Lurasidone/Cycloserine

NRx Pharmaceuticals is developing NRX-101, an FDA-designated Breakthrough Therapy for treatment-resistant bipolar depression with suicidality, with plans to file for Accelerated Approval.

The global bipolar depression market is projected to experience significant growth through 2034, driven by increasing prevalence, with the United States accounting for approximately 85% of the market share across major regions.

NRx Pharmaceuticals subsidiary HOPE Therapeutics announces planned acquisition of Kadima Neuropsychiatry Institute to serve as the flagship for an international network of interventional psychiatry clinics treating depression and PTSD.

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has signed a definitive agreement to acquire Dura Medical, an EBITDA-positive provider of interventional psychiatry services in Florida.

NRx Pharmaceuticals has filed the initial section of its New Drug Application (NDA) to the FDA for NRX-100 (ketamine) to treat suicidal depression.